Intracameral Vigamox (moxifloxacin 0.5%) is not effective in preventing endophthalmitis in a rabbit model.
Laurent
L
Kodjikian
Justus G
JG
Garweg
D000818:Animals; D000867:Anterior Chamber / Q000187:drug effects*; D001372:Aza Compounds / Q000627:therapeutic use*; D015169:Colony Count, Microbial; D004195:Disease Models, Animal; D009877:Endophthalmitis / Q000382:microbiology / Q000517:prevention & control*; D015818:Eye Infections, Bacterial / Q000382:microbiology / Q000517:prevention & control*; D024841:Fluoroquinolones; D007267:Injections; D000077266:Moxifloxacin; D019055:No-Observed-Adverse-Effect Level; D011804:Quinolines / Q000627:therapeutic use*; D011817:Rabbits; D013203:Staphylococcal Infections / Q000382:microbiology* / Q000517:prevention & control*
D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D000077266:Moxifloxacin